{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T04:19:55Z","timestamp":1778300395942,"version":"3.51.4"},"reference-count":43,"publisher":"Massachusetts Medical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NEJM Evidence"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1056\/evidoa2400380","type":"journal-article","created":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T17:00:26Z","timestamp":1733677226000},"source":"Crossref","is-referenced-by-count":5,"title":["BNC210, an \u03b17 Nicotinic Receptor Modulator, in Post-Traumatic Stress Disorder"],"prefix":"10.1056","volume":"4","author":[{"given":"Spyridon","family":"Papapetropoulos","sequence":"first","affiliation":[{"name":"Bionomics Limited, Adelaide, SA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Doolin","sequence":"additional","affiliation":[{"name":"Bionomics Limited, Adelaide, SA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Bionomics Limited, Adelaide, SA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dharam","family":"Paul","sequence":"additional","affiliation":[{"name":"Bionomics Limited, Adelaide, SA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Odontiadis","sequence":"additional","affiliation":[{"name":"Bionomics Limited, Adelaide, SA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Jaros","sequence":"additional","affiliation":[{"name":"Summit Analytical, Denver"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Rolan","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Consulting and University of Adelaide Medical School, Adelaide, SA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray B.","family":"Stein","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and School of Public Health, University of California, San Diego, La Jolla"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"150","reference":[{"key":"e_1_3_4_2_2","volume-title":"Diagnostic and statistical manual of mental disorders, text revision DSM-5-TR","author":"American Psychiatric Association","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, text revision DSM-5-TR. 5th ed. Washington, DC: American Psychiatric Association, 2022.","edition":"5"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-016-1208-5"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291717000708"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.21273"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20240536"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph15071425"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-020-01184-x"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14116"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-020-00281-0"},{"key":"e_1_3_4_11_2","volume-title":"Pharmacologic and nonpharmacologic treatments for posttraumatic stress disorder: 2023 update of the evidence base for the PTSD trials standardized data repository","unstructured":"O\u2019Neil ME, Cheney TP, Yu Y, et al. Pharmacologic and nonpharmacologic treatments for posttraumatic stress disorder: 2023 update of the evidence base for the PTSD trials standardized data repository. Systematic Review. AHRQ Publication No. 23-EHC028. Rockville, MD: Agency for Healthcare Research and Quality, 2023."},{"key":"e_1_3_4_12_2","unstructured":"Department of Veterans Affairs and Department of Defense. Clinical practice guideline for management of posttraumatic stress disorder and acute stress disorder. Washington DC: Department of Veterans Affairs and Department of Defense 2023."},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1017\/S003329171700349X"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002795.pub3"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2022.110557"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.107.048371"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2017.03.007"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.17080955"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2024.109836"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2192922"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-01141-5"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2019.12.013"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2006.118232"},{"key":"e_1_3_4_24_2","unstructured":"Papapetropoulos S Doolin E Odontiadis M et al. A Phase 2 double-blind placebo-controlled study for BNC210 an alpha7 nicotinic receptor negative allosteric modulator (NAM) for the acute treatment of social anxiety disorder (PREVAIL). Poster presented at the American Society of Clinical Psychopharmacology Annual Meeting 2023 May 3\u2013June 2 2023 Miami FL."},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","unstructured":"Kremmidiotis G Doolin E Metzger D Drutinus E Danjou P O\u2019Connor S. A double-blind double dummy placebo and positive-controlled randomised 4-way crossover study to evaluate the pharmacodynamic effects of single oral doses of the novel anxiolytic compound BNC210 in healthy male volunteers. Poster presented at the 24th European College of Neuropsychopharmacology September 3\u20137 2011 Paris France.","DOI":"10.1016\/S0924-977X(11)70859-8"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1037\/pas0000486"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"e_1_3_4_28_2","unstructured":"Weathers FW Litz BT Keane TM Palmieri PA Marx BP Schnurr PP. The PTSD checklist for DSM-5 (PCL-5). National Center for PTSD 2013 (https:\/\/www.ptsd.va.gov\/)."},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"e_1_3_4_30_2","volume-title":"ECDEU assessment manual for psychopharmacology","unstructured":"Guy W.. ECDEU assessment manual for psychopharmacology. Rockville, MD: Department of Health, Education, and Welfare, 1976."},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1389-9457(00)00065-4"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199606003-00015"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"e_1_3_4_34_2","first-page":"P29","article-title":"Pharmacometrics analysis and drug reformulation of BNC210 to optimize its evaluation in a Phase 2 trial in PTSD patients","volume":"47","year":"2022","unstructured":"Doolin E, Paul D, O\u2019Connor S, et al. Pharmacometrics analysis and drug reformulation of BNC210 to optimize its evaluation in a Phase 2 trial in PTSD patients. Neuropsychopharmacology 2022;47:P29.","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20081"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1080\/20008066.2023.2222608"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2020.07.046"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2023.110754"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/jts.22360"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.3928\/00485713-20231012-01"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.0951"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010753.pub2"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X21666230801144328"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1037\/a0031474"}],"container-title":["NEJM Evidence"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T22:54:53Z","timestamp":1769727293000},"score":1,"resource":{"primary":{"URL":"https:\/\/evidence.nejm.org\/doi\/10.1056\/EVIDoa2400380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1056\/EVIDoa2400380"],"URL":"https:\/\/doi.org\/10.1056\/evidoa2400380","relation":{},"ISSN":["2766-5526"],"issn-type":[{"value":"2766-5526","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}